Protara Therapeutics, Inc. (TARA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.94-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating expenses and cash burn: TTM operating cash flow -$45.2M vs target no worse than -$21.3M.
Protara aims to complete enrollment of its ADVANCED-2 trial by 2H 2026. Operating losses are expected around -$19.6M in 2026-Q1, reflecting investment in clinical progress. Recent earnings beats in 2025 show some operational improvements. The company is focused on advancing its cancer and rare disease therapies.
Operating losses worsened from -$10.7M in 2024-Q2 to -$19.6M in 2026-Q1. Cash burn increased from -$7.7M to -$21.3M over the same period. The company remains unprofitable with no revenue and uncertain trial outcomes. Key management departures add risk to execution.
The market is selling off the stock amid high losses and no revenue, reflecting skepticism on trial progress and cash burn. There is no clear consensus revenue or EPS growth priced in, and the stock lacks a defined fair value in the desk.
Breaks if: Negative or inconclusive trial results
Breaks if: Operating loss or cash burn significantly worse than -$19.6M or -$21.3M in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious due to recent earnings misses and elevated risk levels.
The market seems to be pricing in a challenging outlook, with expectations for continued losses and weak financial performance. Recent events, including an earnings miss, have likely contributed to a muted price reaction.
Fundamentals are likely to remain under pressure in the near term, given the company's loss-making status and weak recent performance. Management's focus on completing clinical trials and regulatory submissions may provide some long-term potential, but immediate results are uncertain.
The thesis hinges on management's ability to execute on key milestones, such as trial enrollments and reporting interim results. Additionally, broader sector performance and economic conditions, particularly job growth, will influence TARA's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. Recent financial performance remains weak, sitting well below its industry cohort.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Control operating expenses and cash burn to support operations into 2028 with cash and investments of approximately $162 million as of 2026-Q2.
Stated as a priority in 2 of last 2 quarters. Cash and investments declined from approximately $177 million in 2026-Q1 to $162 million in 2026-Q2, reflecting cash burn. Operating expenses increased from $19.6 million to $23.3 million over the same period. Management expects cash to support operations into 2028. The trajectory shows ongoing cash use consistent with clinical development.
“Cash, cash equivalents and investments of approximately $162 million as of June 30, 2026, expected to support planned operations into 2028.”
“Cash, cash equivalents and investments of approximately $177 million as of March 31, 2026, expected to support planned operations into 2028.”
Breaks if: Enrollment not completed by end of 2026-H2
Complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in the fourth quarter of 2026.
Stated as a priority in 2 of last 2 quarters. Management expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial by 4Q 2026. This timeline is consistent across the two most recent quarters. No revenue is reported yet, consistent with ongoing enrollment. The trajectory matches management's stated timeline.
“Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026.”
“Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in the second half of 2026.”
In the next 1 to 3 years, TARA faces significant challenges but could benefit from positive sector momentum and successful trial outcomes. Not investment advice.